Compounded GLP-1 State Laws: Who Restricts What
California codified a stricter copy rule, Ohio suspended 30+ licenses, Washington issued stop-service orders. The state layer now gates compounded GLP-1s.
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
New articles delivered to your inbox every morning. Free.
California codified a stricter copy rule, Ohio suspended 30+ licenses, Washington issued stop-service orders. The state layer now gates compounded GLP-1s.
A 15-month-old vendor with unusually strong lab documentation and almost no reputation yet. What their COAs really show, and how the pricing compares.
Novo's amylin/GLP-1 combo matched tirzepatide on weight but missed on blood sugar in the 68-week REIMAGINE 4 head-to-head. What it means for buyers.
Pfizer axed its ex-Metsera oral GLP-1 peptide and a phase 2 GIPR antagonist. What survived the cut, and what it changes for research-peptide sourcing.
48% of physicians say patients disclosed peptide use last year — and 84% got their information from influencers, not doctors. The full survey data.
3,596 daily price observations across 9 vendors and 56 peptides — median $/mg, volatility bands, and a 12.2% stockout rate. Trailing 90 days.
The FDA's plan to bar 503B bulk compounding of semaglutide, tirzepatide and liraglutide drew 3,901 comments before the July 30 cutoff. What survives.
The FDA published 17 revised generic-peptide guidances and pulled its 2021 synthetic-peptide rule. What it changes for GLP-1 pricing and access.
Novo asked a court to halt Lilly's GLP-1 ads for pitting max-dose tirzepatide against outdated semaglutide doses. What the trial data actually shows.
Leerink pegs compounded peptides at a $2.2B telehealth market and Hims jumped 10% on the FDA vote. What the prescription route means for price and timing.
Most peptides aren't FDA-approved drugs — which isn't the same as illegal. The plain-English answer, and what the FDA's July vote did and didn't change.
Card networks keep dropping peptide sellers, so crypto is now the default. Which vendors take Bitcoin, who adds a crypto discount, and how it works.
Lilly's retatrutide met endpoints in two Phase 3 trials — up to 22.6% weight loss in obesity with diabetes and heart disease. What buyers should know.
FDA advisers backed 6 of 7 peptides for compounding — Semax and Epitalon included — and rejected DSIP, all over staff objections. Every vote tally.
Boehringer's BI 3034701, a GLP-1/GIP/NPY2 triple agonist, entered Phase 2 for obesity. How it differs from retatrutide and what buyers can get now.
The Phase 2 trial reported oral quadruple agonist NA-931 hit 13.8% weight loss with no muscle loss. How it stacks up to retatrutide.
BPC-157, MOTS-c and microdosed GLP-1s are marketed for Long COVID while semaglutide and tirzepatide trials run. What's studied, what isn't.
4.7 on Trustpilot — but seven buyers report the retatrutide did nothing. What the star average hides, plus working codes at vendors we do recommend.